Drug-eluting stents - Pushing the envelope beyond the labels?

New England Journal of Medicine

Volumn 358, Issue 4, 2008, Pages 405-407

  Carrozza Jr , Joseph P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEVICE THERAPY; DRUG ELUTING STENT; EDITORIAL; FEMALE; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETREATMENT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; DRUG LABELING; NOTE; STATISTICS; STENT;

CORONARY ARTERY BYPASS; CORONARY DISEASE; DRUG LABELING; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; STENTS;

EID: 38549112622     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0708247     Document Type: Editorial

References (14)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
2. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
3. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
4. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
5. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-9.
6. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting
7. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
8. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N Engl J Med 2007;356:984-7.
9. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008;358:331-41.
10. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005;352:2174-83.
11. Bravata DM, Gienger AL, McDonald KM, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med 2007;147:703-16.
12. King SB III, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med 1994;331:1044-50.
13. Hamm CW, Reimers J, Ischinger T, Rupprecht H-J, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multi-vessel coronary disease. N Engl J Med 1994;331:1037-43.
14. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008;358:342-52.